Gå direkt till huvudinnehållet

Mani och bipolär sjukdom

Senast uppdaterad: Senast reviderad:
Sakkunnig:
Definition:
Perioder med mani (bipolär typ I) eller hypomani (bipolär typ II) och perioder med depression, med bra perioder däremellan. Vid bipolär typ I krävs inte perioder med depression för diagnos.
Förekomst:
Livstidsprevalensen är cirka 1 %.
Symtom:
Vid mani/hypomani ihållande och abnorm förhöjd, expansiv eller irritabel sinnesstämning. Vid depression ihållande sänkt stämningsläge, brist på intresse och glädje samt energiförlust och/eller ökad trötthet.
Kliniska fynd:
En manisk patient är ofta mycket orolig, ibland aggressiv, och det kan vara svårt att föra ett normalt samtal.
Diagnostik:
Strukturerade eller semistrukturerade intervjuformulär bör användas.
Behandling:
Behandlingen är en kombination av läkemedel och psykologisk behandling.
  1. Sanai-Farid S, Backlund L. ABC om Bipolär sjukdom. Lakartidningen.se 2019-03-05 lakartidningen.se  
  2. Adler M (redaktör). Bipolär sjukdom. Kliniska riktlinjer för utredning och behandling. Sundsvall/Stockholm: Svenska psykiatriska föreningen/Gothia Fortbildning; 2014 www.svenskpsykiatri.se  
  3. Morken G, Vaaler AE, Folden GE, Andreassen OA, Malt UF. Age at onset of first episode and time to treatment in in-patients with bipolar disorder. Br J Psychiatry 2009; 194: 559-60. PubMed  
  4. Larsson S, Lorentzen S, Mork E, et al. Age at onset of bipolar disorder in a Norwegian catchment area sample. J Affect Disord 2010; 124: 174-7. PubMed  
  5. Berle JØ, Solberg DK, Spigset O. Behandling av bipolar lidelse under svangerskap og etter fødsel. Tidsskr Nor Legeforen 2011; 131: 126-9. Tidsskrift for Den norske legeforening  
  6. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 suppl): 1-50. PMID: 11958165 PubMed  
  7. Parikh SV, LeBlanc SR, Ovanessian MM. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Can J Psychiatry 2010; 55: 136-43. PubMed  
  8. Fiedorowicz JG, Solomon DA, Endicott J, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 2009; 71: 598-606. PubMed  
  9. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-247. PubMed  
  10. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164: 331-43. PubMed  
  11. Sklar P, Ripke S, Scott LJ, et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nature genetics 2011; doi:10.1038/ng.943. DOI  
  12. Van Snellenberg JX, de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch Gen Psychiatry 2009; 66: 748-55. PubMed  
  13. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60: 497-502. PubMed  
  14. Proudfoot J, Doran J, Manicavasagar V, Parker G. The precipitants of manic/hypomanic episodes in the context of bipolar disorder: a review. J Affect Disord. 2010.
  15. Viguera AC, Nonacs R, Cohen LS et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157: 179-84. American Journal of Psychiatry  
  16. Viguera AC, Tondo L, Baldessarini RJ. Sex differences in response to lithium treatment. Am J Psychiatry 2000; 157: 1509-11. American Journal of Psychiatry  
  17. Frans EM, Sandin S, Reichenberg A, Lichtenstein P, Långström N, Hultman CM. Advancing paternal age and bipolar disorder. Arch Gen Psychiatry 2008; 65: 1034-40. PubMed  
  18. SBU. Diagnostik och uppföljning av förstämningssyndrom (2012). www.sbu.se  
  19. Lam DH, Watkins ER, Hayward P et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60: 145-52. PubMed  
  20. Colom F, Vieta E, Martínez-Arán A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-7. PubMed  
  21. Miklowitz DJ, George EL, Richards JA et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60: 904-12. PubMed  
  22. Underhållsbehandling med nyare antipsykotiska läkemedel vid bipolär sjukdom. Statens beredning för medicinsk och social utvärdering (SBU). 2015 www.sbu.se  
  23. Suttajit S, Srisurapanont M, Maneeton N et al. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827-38. PubMed  
  24. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-60. American Journal of Psychiatry  
  25. Brown E, Dunner DL; McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2008; Dec 11: 1-10.
  26. Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission The STOP-PD II Randomized Clinical Trial. JAMA 2019; 322: 622-31. pmid:31429896 PubMed  
  27. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9. British Journal of Psychiatry  
  28. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-55. PubMed  
  29. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013 Jun 27;346:f3646. doi:10.1136/bmj.f3646. DOI  
  30. Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007; 11: 1-226. PubMed  
  31. Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62: 860-6. PubMed  
  32. Saunders KE, Geddes JR. The management of bipolar disorder. Br J Hosp Med (Lond). 2016 Mar;77(3):175-9
  33. Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 2015 ; Jun;20(6): 661-70. pmid:25687772 PubMed  
  34. Lähteenvuo M, Tanskanen A, Taipale H, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry 2018 Feb 28; doi: 10.1001/jamapsychiatry.2017.4711: Epub ahead of print. pmid:29490359 PubMed  
  35. Hayes JF, Pitman A, Marston L et al. Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment A UK Population-Based Electronic Health Records Study. JAMA Psychiatry 2016; 73: 630-7. pmid:27167638 PubMed  
  36. Hashimoto Y, Kotake K, Watanabe N, et al. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2021 Sep 15;9:CD013575. doi: 10.1002/14651858.CD013575.pub2 DOI  
  37. Lam DH, Hayward P, Watkins ER, et al. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry 2005; 162: 324-9. American Journal of Psychiatry  
  38. Castle D, White C, Chamberlain J, et al. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry 2010; 196: 383-8. British Journal of Psychiatry  
  39. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318:149-153. British Medical Journal  
  40. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442. PubMed  
  41. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Women Ment Health 2005; 8: 77-87. PubMed  
  42. Tohen M, Hennen J, Zarate C, et al. Harvard first episodes project: predictors of recovery and relapse. Bipolar Disord 2002;4(suppl 1):135-136. PMID: 14638578 PubMed  
  43. Solberg DK, Refsum H. Oppfølging av pasienter som bruker litium. Tidsskr Nor Legeforen 2008; 128: 1410-2. PubMed  
  44. Reinares M, Bonnín CM, Hidalgo-Mazzei D, et al. The role of family interventions in bipolar disorder: A systematic review. Clin Psychol Rev. 2016 Feb;43:47-57. Epub 2015 Dec 3. pmid: 26691629 PubMed  
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet

Tidigare sakkunniga

  • Hans Ågren, professor emeritus och överläkare, sektionen för psykiatri och neurokemi, Sahlgrenska akademin, Göteborgs universitet
  • Randolf Terje Vågen, medisinsk fagsjef, Divisjon psykisk helsevern, St. Olavs hospital
  • Ingard Løge, spesialist allmennmedisin, redaktør Norsk Elektronisk Legehåndbok